To highlight the launch and benefits of the FDA-approved noninvasive epithelium-on corneal cross-linking treatment for keratoconus, known as Epioxa.
Approach:
Product Overview: Epioxa HD/Epioxa is a topical therapy using riboflavin solutions catalyzed by enriched oxygen and light, designed to improve patient comfort and recovery time.
Procedure Description: The procedure involves the application of Epioxa HD and Epioxa eye drops in combination with the O₂n System and Boost Goggles, performed by an ophthalmologist.
Expert Insights: Cody McKenzie from Glaukos emphasizes the importance of early intervention and patient support programs, while Dr. Mitch Ibach discusses the favorable safety profile and faster recovery associated with Epioxa.
Key Findings:
Epioxa reduces pain associated with corneal epithelium removal and streamlines the procedure.
The treatment is designed to slow or halt keratoconus progression and improve visual recovery.
Early referral for imaging is crucial when keratoconus is suspected, especially in young patients.
Limitations:
The labeling for Epioxa does not specify 'progressive keratoconus', which may affect treatment protocols.
Further experience with postoperative protocols is needed as clinicians adapt to the new treatment.
